Neurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $164.00 by Analysts at Canaccord Genuity Group

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its target price hoisted by research analysts at Canaccord Genuity Group from $154.00 to $164.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 17.29% from […]

Related Keywords

United States ,Ingrid Delaet ,Neurocrine Biosciences ,Kevin Charles Gorman ,Canaccord Genuity Group ,Edgerock Capital ,Barclays ,Jpmorgan Chase Co ,Neurocrine Biosciences Inc ,Mather Group ,Lindbrook Capital ,Benjaminf Edwards Company Inc ,Goldman Sachs Group ,Securities Exchange Commission ,Get Free Report ,Genuity Group ,Charles Gorman ,Exchange Commission ,Rock Capital ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Boost Price Target ,Canaccord Genuity Group Inc ,